A clinical case of effective treatment of giant prolactinoma in patient with morbid obesity
https://doi.org/10.14341/omet2014235-39
Abstract
Numerous studies showed an association between prolactin levels and body weight, with increased prevalence of obesity in patients with prolactinomas. Recent data indicate potential positive influence of cabergoline treatment to metabolic disorders in these patients. This clinical case demonstrates of a man with morbid obesity and giant prolactinoma which was successfully treated by high-dose cabergoline.
About the Authors
S VorotnikovaEndocrinology Research Centre
L Dzeranova
Endocrinology Research Centre
E Pigarova
Endocrinology Research Centre
N Markina
Endocrinology Dispenser of Moscow's Department of healthcare
References
1. Марова Е.И., Мокрышева Н.Г., Дзеранова Л.К., Панков Ю.А., Кеда Ю.М. Влияние гиперпролактинемии опухолевого генеза на состояние жирового обмена. Ожирение и метаболизм. 2005;3:33-38.
2. Насыбуллина Ф.А., Вагапова Г.Р., Пашаев Б.Ю., Бочкарев Д.В. Гендерные особенности клинического течения пролактин-секретирующих аденом гипофиза. Практическая медицина. 2012;9 (65):120-123.
3. Романцова Т.И. Репродукция и энергетический баланс: интегративная роль пролактина. Метаболизм и ожирение. 2014; 1.
4. Auriemma R.S., Granieri L., Galdiero M., Simeoli C., Perone Y., Vitale P., Pivonello C., Negri M., Mannarino T., Giordano C., Gasperi M., Colao A., Pivonello R. Effect of Cabergoline on Metabolism in Prolactinomas. Neuroendocrinology. 2013 [Epub ahead of print].
5. Ciresi A., Amato M.C., Guarnotta V., Lo Castro F., Giordano C. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf). 2013; Mar 18.
6. De Rosa M., Zarrilli S., Di Sarno A., Milano N., Gaccione M., Boggia B., Lombardi G., Colao A. Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine. 2003;20 (1-2):75-82.
7. Inancli S., Usluogullari A., Ustu Y., Caner S., Tam A., Ersoy R., Cakir B. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 2013;44 (1):193-199.
8. Kelly D.M., Jones T.H. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217(3):25-45.
9. Maiter D., Delgrange E. The challenges in managing giant prolactinomas. Eur J Endocrinol. 2014 [Epub ahead of print].
10. Moraes A.B., Silva C.M., Vieira Neto L., Gadelha M.R. Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf). 2013;79(4):447-56.
11. Shibli-Rahhal A., Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary. 2009;12:96-104.
Review
For citations:
, , , A clinical case of effective treatment of giant prolactinoma in patient with morbid obesity. Obesity and metabolism. 2014;11(2):35-39. (In Russ.) https://doi.org/10.14341/omet2014235-39
Views:
516
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
